Sleep research article
Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double-Blinded, Placebo-Controlled Crossover Study.
Authors: Hansen PN , Markvardsen L , Tankisi H , Andersen H , Krøigård T , Sindrup S
One-line summary
A sleep science research article on Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double-Blinded, Placebo-Controlled Crossover Study..
Sleep health notes
Sleep health notes will be added by the Sleepatch editorial team.
中文解读
中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。
Original abstract
<h4>Background and aims</h4>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated neuropathy that may cause persistent disability despite immunoglobulin treatment. Ion channel dysfunction has been demonstrated in CIDP, but no therapies specifically target this mechanism. We investigated whether fampridine improves clinical function and electrophysiological measures in CIDP patients with residual symptoms.<h4>Methods</h4>In this two-center, randomized, double-blind, placebo-controlled crossover trial, patients with CIDP receiving stable subcutaneous or intravenous immunoglobulin were assigned to 4 weeks of fampridine (10 mg twice daily) or placebo, separated by a washout period. Co-primary outcomes were changes in Six-Spot-Step Test (SSST) and Nine-Hole Peg Test (9-HPT). Secondary outcomes included clinical scores, patient-reported outcomes, nerve conduction studies, and nerve excitability testing.<h4>Results</h4>Twenty-eight patients were included in the study. No significant differences were observed between fampridine and placebo for SSST (p = 0.154) or 9-HPT (p = 0.857). Grip strength and R-ODS worsened during fampridine compared with placebo (Bonferroni-adjusted p = 0.007 for both), while other clinical outcomes showed no differences. Median nerve CMAP amplitude with proximal stimulation increased significantly during fampridine treatment (adjusted p = 0.040). No significant changes were observed in other electrophysiological variables, including nerve excitability testing. No serious adverse events occurred and adverse effects were predominantly mild.<h4>Interpretation</h4>Our study did not provide evidence that fampridine improves clinical function in CIDP patients with residual disability during stable immunoglobulin therapy. Targeting ion channel dysfunction in CIDP remains of interest, but alternative strategies may be required.
Links and sources
This content is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sleep disorders, chronic insomnia, sleep apnea, and other conditions must be evaluated and treated by a qualified healthcare professional. If you experience persistent or severe sleep problems, consult a licensed physician or sleep specialist. Research cited refers to peer-reviewed studies; individual results may vary. Sleepatch does not endorse any specific medication, supplement, or therapy.
Want a personalized sleep improvement plan?
Sleepatch can prepare a customized sleep wellness program, insomnia relief guide, and evidence-based sleep coaching based on your needs.
Explore sleep services
Comments